Antiplasmodial Activity Evaluation of a Bestatin-Related Aminopeptidase Inhibitor, Phebestin.

The increasing burden and spread of resistant malaria parasites remains an immense burden to public health. These factors have driven the demand to search for a new therapeutic agent. From our screening, phebestin stood out with nanomolar efficacy against Plasmodium falciparum 3D7. Phebestin was initially identified as an aminopeptidase N inhibitor. Phebestin inhibited the in vitro multiplication of the P. falciparum 3D7 (chloroquine-sensitive) and K1 (chloroquine-resistant) strains at IC50 values of 157.90 ± 6.26 nM and 268.17 ± 67.59 nM, respectively. Furthermore, phebestin exhibited no cytotoxic against human foreskin fibroblast cells at 2.5 mM. In the stage-specific assay, phebestin inhibited all parasite stages at 100 and 10-fold its IC50 concentration. Using 72-h in vitro exposure of phebestin at concentrations of 1 µM on P. falciparum 3D7 distorted the parasite morphology, showed dying signs, shrank, and prevented reinvasion of RBCs, even after the compound was washed from the culture. An in silico study found that phebestin binds to P. falciparum M1 alanyl aminopeptidase (PfM1AAP) and M17 leucyl aminopeptidase (PfM17LAP), as observed for bestatin. In vivo evaluation using P. yoelii 17XNL-infected mice with administrations of 20 mg/kg phebestin, once daily for 7 days, resulted in significantly lower parasitemia peaks in the phebestin-treated group (19.53%) than in the untreated group (29.55%). At the same dose and treatment, P. berghei ANKA-infected mice showed reduced parasitemia levels and improved survival compared to untreated mice. These results indicate that phebestin is a promising candidate for development as a potential therapeutic agent against malaria.

Sparsomycin Exhibits Potent Antiplasmodial Activity In Vitro and In Vivo.

The emerging spread of drug-resistant malaria parasites highlights the need for new antimalarial agents. This study evaluated the growth-inhibitory effects of sparsomycin (Sm), a peptidyl transferase inhibitor, against Plasmodium falciparum 3D7 (chloroquine-sensitive strain), P. falciparum K1 (resistant to multiple drugs, including chloroquine), P. yoelii 17XNL (cause of uncomplicated rodent malaria) and P. berghei ANKA (cause of complicated rodent malaria). Using a fluorescence-based assay, we found that Sm exhibited half-maximal inhibitory concentrations (IC50) of 12.07 and 25.43 nM against P. falciparum 3D7 and K1, respectively. In vitro treatment of P. falciparum 3D7 with Sm at 10 or 50 nM induced morphological alteration, blocked parasites in the ring state and prevented erythrocyte reinvasion, even after removal of the compound. In mice infected with P. yoelii 17XNL, the administration of 100 µg/kg Sm for 7 days did not affect parasitemia. Meanwhile, treatment with 300 µg/kg Sm resulted in a significantly lower parasitemia peak (18.85%) than that observed in the control group (40.13%). In mice infected with P. berghei ANKA, both four and seven doses of Sm (300 µg/kg) prolonged survival by 33.33%. Our results indicate that Sm has potential antiplasmodial activities in vitro and in vivo, warranting its further development as an alternative treatment for malaria.

Metacytofilin has potent anti-malarial activity.

Metacytofilin (MCF) was isolated from the fungus Metarhizium sp. TA2759. Although MCF possesses anti-Toxoplasma activity, the effects of this compound against other parasites are unknown. Here, we evaluated the in vitro anti-malarial activity of MCF against the 3D7 strain and the chloroquine-resistant K1 strain of Plasmodium falciparum. The half maximal inhibitory concentrations (IC50) of MCF against the 3D7 and K-1 strains following culture for 48 h were 666 nM and 605 nM, respectively. Artemisinin was more potent than MCF against both strains (3D7 IC50: 17.4 nM; K-1 IC50: 18.3 nM), while chloroquine was ineffective against the chloroquine-resistant strain (3D7 IC50: 39.1 nM; K-1 IC50: 1.62 µM). MCF affected the ring stage of the parasites, resulting in their death as shown by spots within red blood cells. MCF also inhibited parasite growth following culture for 72 h (3D7 IC50, 285 nM). Four optical isomers of cyclo[Leu-Phe]-diketopiperazine derivatives with modified methoxy and/or hydroxyl groups lost anti-malarial activity, suggesting that the spatial positions of the methoxy and hydroxyl groups in MCF play an important role in its anti-malarial effects. Together, these data suggest that MCF may represent a promising lead compound for treatment of drug-resistant malarial parasites.

Metacytofilin Is a Potent Therapeutic Drug Candidate for Toxoplasmosis.

BACKGROUND: Toxoplasmosis, a parasitic disease caused by Toxoplasma gondii, is an important cause of miscarriage or adverse fetal effects, including neurological and ocular manifestations in humans. Current anti-Toxoplasma drugs have limited efficacy against toxoplasmosis and also have severe side effects. Therefore, novel efficacious drugs are urgently needed. Here, we identified metacytofilin (MCF) from a fungal Metarhizium species as a potential anti-Toxoplasma compound. METHODS: Anti-Toxoplasma activities of MCF and its derivatives were evaluated in vitro and in vivo using nonpregnant and pregnant mice. To understand the mode of action of MCF, the RNA expression of host and parasite genes was investigated by RNAseq. RESULTS: In vitro, MCF inhibited the viability of intracellular and extracellular T. gondii. Administering MCF intraperitoneally or orally to mice after infection with T. gondii tachyzoites increased mouse survival compared with the untreated animals. Remarkably, oral administration of MCF to pregnant mice prevented vertical transmission of the parasite. Interestingly, RNA sequencing of T. gondii-infected cells treated with MCF showed that MCF inhibited DNA replication and enhanced RNA degradation in the parasites. CONCLUSIONS: With its potent anti-T. gondii activity, MCF is a strong candidate for future drug development against toxoplasmosis.

Isolation and characterization of antiprotozoal compound-producing Streptomyces species from Mongolian soils.

Natural resources are recognized as important sources of potential drugs for treating various infections, and microorganisms are a rich natural source of diverse compounds. Among the world's microorganisms, actinomycetes, which are abundant in soil and marine, are the well-known producers of a wide range of bioactive secondary metabolites and antibiotics. In the present study, four actinomycetes (samples N25, N6, N18, and N12) were isolated from soil samples in Mongolia. Phylogenetic analysis of these isolates revealed that they share the highest similarity with Streptomyces canus (N25), S. cirratus (N6), S. bacillaris (N18) and S. peucetius (N12), based on 16S rRNA gene sequencing. Crude extracts were obtained from them using ethyl acetate, and the crude fractions were separated by thin layer chromatography. The fractions were then evaluated for their cytotoxicities and their anti-Toxoplasma and antimalarial activities in vitro. The S. canus (N25) crude extract was selected for further chemical characterization based on its antiprotozoal activities. Using liquid chromatography-high resolution mass spectrometry, phenazine-1-carboxylic acid (PCA) was detected and identified in the active fractions of the metabolites from strain N25. We next confirmed that commercially available PCA possesses antiprotozoal activity against T. gondii (IC50: 55.5 µg/ml) and Plasmodium falciparum (IC50: 6.4 µg/ml) in vitro. The results of this study reveal that soil actinomycetes are potential sources of antiprotozoal compounds, and that PCA merits further investigation as an anti-protozoal agent.

Seroepidemiological study of Toxoplama gondii in small ruminants (sheep and goat) in different provinces of Mongolia.

Toxoplasmosis is caused by the protozoan parasite Toxoplasma gondii. Consumption of raw or undercooked meat is the main risk factor for acquiring T. gondii infection in humans. Meat and meat products derived from goats and sheep are mainly consumed in Mongolia; however, there is limited epidemiological information on T. gondii infection in small ruminants in this country. The main objective of the present study was to investigate the seroprevalence of T. gondii in sheep and goats in Mongolia. The seroprevalence of T. gondii IgG antibodies was determined by an indirect enzyme-linked immunosorbent assay based on the recombinant antigens of dense granule protein 7 of T. gondii. A total of 1078 goat and 882 sheep blood samples were collected from 17 of 21 provinces and the capital city of Mongolia. Overall, the seroprevalence of T. gondii among the goat and sheep samples was 32% and 34.8%, respectively. The seroprevalence among goat samples was significantly higher in western (42.7%) and eastern (45.6%) regions compared with other regions (24%). Additionally, the seroprevalence among sheep was significantly higher in eastern regions (55.4%) compared with other regions (26%-33%). Age, but not sex, was considered a risk factor for T. gondii seropositivity in goats, whereas no statistically significant differences were observed in sheep for age or sex. In conclusion, the present study demonstrates the high seroprevalence of T. gondii in small ruminants in Mongolia. Our results highlight that country-wide control measures are required to minimize infections in livestock.

Seroprevalence of Toxoplasma gondii and Neospora caninum infections in cattle in Mongolia.

Toxoplasma gondii and Neospora caninum are protozoan parasites that cause huge economic losses in animal industries worldwide. N. caninum can cause abortion storms and high culling rates in cattle, whereas T. gondii infection is a significant concern in both human and animals because it can induce abortion and clinical symptoms in immunocompromised hosts. The aim of this study was to determine the seroprevalence of T. gondii and N. caninum in cattle in Mongolia. Specific antibodies to T. gondii and N. caninum were detected by using an indirect enzyme-linked immunosorbent assay (iELISA) based on recombinant antigens of dense granule protein 7 of Toxoplasma gondii and surface antigen 1 of Neospora caninum, respectively. A total of 1438 cattle sera from 20 of 21 provinces of Mongolia and the capital city of Ulaanbaatar were tested. Overall, 18.7% and 26.2% of cattle were positive for specific antibodies to T. gondii and N. caninum, respectively. Prevalence rates were higher (T. gondii infection: P < .0001, N. caninum infection: P = .002) in the central region of Mongolia (T. gondii infection: 27.1%, N. caninum infection: 30.8%) compared with western region, suggesting that prevalence rates might be influenced by geographical condition, particularly warmer temperatures around this area in Mongolia. The lowest prevalence rates were observed in the western region of Mongolia (T. gondii: 9%, N. caninum: 20.8%). In addition, the seroprevalence of N. caninum in female animals (27.5%) was significantly higher than that in male animals (20.4%) (P = .018), suggesting an important risk factor of abortion and stillbirth in cattle. The present results showed that T. gondii and N. caninum infections might be a risk for public health and economy of the livestock industry in Mongolia. In conclusion, this study demonstrates high seroprevalences of T. gondii and N. caninum in Mongolia and provides valuable new data for development of control measures against these infections in Mongolia.